Company / Current Liabilities
AXIM BIOTECHNOLOGIES, INC. Current Liabilities History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$6.0M
FY2023
5-year range
$3.0M / $7.7M
FY2019-FY2023
Trend
+76.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $3M to $6M over the past 5 years.
Based on SEC 10-K filings.
$6M in FY2023 with a 10-year CAGR of +44.5%.
Increased from $3M to $6M over the past 5 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +12.5%
- 10-Year CAGR
- +44.5%
Key checks
Key Insights
- 5-year CAGR of +12.5%, indicating consistent growth.
- In FY2023, current liabilities increased 76.2% year-over-year.
- Peak current liabilities was recorded in FY2017.
- Lowest current liabilities in the period was in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $6.0M | +76.2% |
| FY2022 | $3.4M | +2.1% |
| FY2018 | $3.3M | -56.9% |
| FY2017 | $7.7M | +155.4% |
| FY2016 | $3.0M | +18.5% |
| FY2015 | $2.5M | +1588.7% |
| FY2013 | $150.7K | +9.6% |
| FY2012 | $137.5K | +8.2% |
| FY2011 | $127.1K | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026